We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -268.00 | -2.18% | 12,028.00 | 12,012.00 | 12,016.00 | 12,266.00 | 11,988.00 | 12,226.00 | 2,197,678 | 16:35:12 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.27 | 186.24B |
From May 2019 to May 2024
By Colin Kellaher
Amgen Inc. and AstraZeneca PLC on Friday reported full positive results from a pivotal Phase 3 trial of tezepelumab, a potential treatment for patients with severe, uncontrolled asthma.
The companies said the study, dubbed "Navigator," showed superiority versus placebo across every primary and key secondary endpoint, with a statistically significant and clinically meaningful reduction in the annualized asthma exacerbation rate in severe, uncontrolled asthma patients.
Amgen and AstraZeneca said tezepelumab is the only biologic to consistently and significantly reduce the exacerbation rate in a broad population of severe asthma patients, and they noted that results from the study will form the basis of regulatory filings for the drug.
U.K. pharmaceutical giant AstraZeneca and Amgen, a Thousand Oaks, Calif., biotechnology company, agreed in 2012 to collaborate on tezepelumab.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
February 26, 2021 09:59 ET (14:59 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
